호흡보정 PET/CT의 유용성에 관한 연구

국문 초록 (Abstract)

PET/CT촬영 시 호흡에 의해 병소의 움직임으로 인한 영상의 왜곡이 발생한다. 본 연구에서는본원에서 보유 하고 있는 호흡보정 Plumonary Toolkit을 이용한 폐결절부위를 영상화 함으로써 보정을 하지 않은 영상과 비교하여 SUV값의 변화와 영상의 왜곡을 어느 정도 교정할 수 있는지 실험하였다. 2008년 5월에서 8월까지 폐암을 진단받은 환자 17명을 대상으로 하였다. 실험결과 Max SUV값은 최소 4.08%에서 최대 43.10%까지의 증가율을 보였고 폐결절 의 평균 Max SUV값은 6.07에서 7.00로 12.16%로 증가가 되었다. 호흡보정 PET/CT의 경우 영상의 왜곡이 개선되었 다. SCC-Adenocarcinoma에서는 호흡보정 전.후에 통계적의로 유의한 수준(P<0.05)을 보였으나 SCC와 Adenocarcinom 에 대한 각각의 비교에서는 유의성을 보이지 않아 Cell type과 관계없이 호흡보정에 효과가 있었다. 실험 결과 Pulmonary Toolkit을 사용할 경우 표준섭취 계수값과 영상에서의 왜곡이 보정되었다. 따라서 폐암의 진단 및 추적관 찰에 도움을 줄 수 있을 것이다.

다국어 초록 (Multilingual Abstract)

When taking PET/CT, the distortion of the image happens due to the movement of a lesion with respiration. In this study, the experiment was conducted to see if the change in SUV value and distortion of the image could be somewhat corrected by comparing the image which was not compensated with that of the region of lung nodule, compensated with respiration compensation Plumonary Toolkit possessed by this hospital. The records of 17 patients with Lung cancer between May and August 2008. As the result of the experiment, Max SUV value increased by from 4.08% minimum to 43.10% maximum, and the average Max SUV value of lung nodule increased from 6.07 to 7.00(12.16%). In the case of respiration compensation PET/CT, the distortion of the image improved. As there was no significance in the comparison of SCC and Adenocarcinom respectively, though there was a statistically significant level(P<0.05) before and after respiration compensation in SCC-Adenocarcinoma, there was an effect in respiration compensation regardless of Cell types. As the result of the experiment, it was found out that the distortion of standard intake coefficient value and the image was compensated Therefore, the diagnosis of lung cancer and follow up will be able to help.

참고문헌 (Reference)

• 1 고창순, "핵의학 2판" 167-168, 1997
• 2 중앙암등록본부, "국가 암 등록 사업 연례보고" 2008
• 3 Boucher L, "Respiratory gating for 3dimensional PET of thorax: Feasibility and initial results" 45 : 214-219, 2004
• 4 Steinert HC, "Non-small cell lung cancer: nodal staging With FDG PET versus CT with correlative lymph node mapping and sampling" 202 : 441-446, 1997
• 5 Vansteenkiste JF, "Lymph nod staging in non-small-celllung cancer with FDG PET scan: A prospective study on 690 lymph node stations from 68 patients"
• 6 Nehmeh SA, "Effect of respiratory gating on quantifying PET images of lung cancer" 43 : 876-881, 2002
• 7 Lowe VJ, "Duhaylongsod FG, Patz EF et al. Pulmonary abnormalities and PET data analysis: a retrospective study" 202 : 435-439, 1997
• 8 Webb WR, "CT and MR imaging in staging non-small cell bronchogenic carcinoma: report of the Radiologic Diagnostic Oncology Group" 178 : 705-713, 1991
• 9 TMcloud TC, "Bronchogenic carrinoma: analysis of staging in the mediastinum with CT by correlative lymph node mapping and sampling" 182 : 319-323, 1992
• 10 Dirk-Hellwing, "18F-FDG PET for Mediastinal Staging of Lung Cancer : Which SUV Threshold makes sense?" 48 : 1761-1766, 2007